| Original language | English |
|---|---|
| Number of pages | 2 |
| Journal | Journal of Clinical Oncology |
| Volume | 36 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 10 Feb 2018 |
| Event | ASCO-SITC Clinical Immuno-Oncology Symposium - San Francisco, Canada Duration: 25 Jan 2018 → 27 Jan 2018 |
Cite this
}
A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. / Friedlander, Michael; Meniawy, Tarek; Markman, Ben; Mileshkin, Linda R.; Harnett, Paul; Millward, Michael; Lundy, J.; Freimund, A. E.; Norris, C.; Mu, S; Paton, V; Wang, L; Gao, Bo.
In: Journal of Clinical Oncology, Vol. 36, No. 5, 10.02.2018.Research output: Contribution to journal › Abstract/Meeting Abstract
TY - JOUR
T1 - A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
AU - Friedlander, Michael
AU - Meniawy, Tarek
AU - Markman, Ben
AU - Mileshkin, Linda R.
AU - Harnett, Paul
AU - Millward, Michael
AU - Lundy, J.
AU - Freimund, A. E.
AU - Norris, C.
AU - Mu, S
AU - Paton, V
AU - Wang, L
AU - Gao, Bo
PY - 2018/2/10
Y1 - 2018/2/10
U2 - 10.1200/JCO.2018.36.5_suppl.48
DO - 10.1200/JCO.2018.36.5_suppl.48
M3 - Abstract/Meeting Abstract
VL - 36
JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
SN - 0732-183X
IS - 5
ER -